Discontinuation Rates

INDICATION

DESCOVY® for HIV-1 pre-exposure prophylaxis (PrEP) is indicated in at-risk adults and adolescents (≥35 kg) to reduce the risk of sexually acquired HIV-1 infection, excluding individuals at risk from receptive vaginal sex. HIV-1–negative status must be confirmed immediately prior to initiation.

Limitation of Use: DESCOVY FOR PrEP is not indicated in individuals at risk of HIV-1 from receptive vaginal sex because effectiveness in this population has not been evaluated.

Few discontinuations due to adverse events1

Discontinuation rates through primary analysis*


1%

of patients discontinued
DESCOVY FOR PrEP™
(n=2694)

VS

2%

of patients discontinued
TRUVADA®
(n=2693)

*Primary analysis: when 100% of patients reached Week 48 and ≥50% reached Week 96